|Dr. Marc H. Hedrick M.D.||Chief Exec. Officer, Pres and Director||596.25k||N/A||54|
|Mr. Tiago M. Girao||Chief Financial Officer and VP of Fin.||344.56k||N/A||38|
|Mr. John D. Harris||VP and Gen. Mang. of Cell Therapy||551.44k||N/A||48|
|Dr. John K. Fraser Ph.D.||Chief Scientist||N/A||N/A||56|
|Mr. Jeremy B. Hayden||Chief Compliance Officer, VP of Bus. Devel., Gen. Counsel and Sec.||N/A||N/A||47|
Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments. The company also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposis Sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer. It serves hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through direct sales force, third-party distributors, independent sales representatives, and partners worldwide. The company was founded in 1996 and is headquartered in San Diego, California.
Cytori Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.